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Abstract: X-chromosome is often excluded from the so called ‘whole-
genome’ association studies due to its intrinsic difference between males
and females. One particular analytical challenge is the unknown status of
X-inactivation, where one of the two X-chromosome variants in females may
be randomly selected to be silenced. In the absence of biological evidence
in favour of one specific model, we consider a Bayesian model averaging
framework that offers a principled way to account for the inherent model
uncertainty, providing model averaging-based posterior density intervals
and Bayes factors. We examine the inferential properties of the proposed
methods via extensive simulation studies, and we apply the methods to a
genetic association study of an intestinal disease occurring in about twenty
percent of Cystic Fibrosis patients. Compared with the results previously
reported assuming the presence of inactivation, we show that the proposed
Bayesian methods provide more feature-rich quantities that are useful in
practice.
Keywords and phrases: Bayesian methods, Model uncertainty, Bayesian
model averaging, Bayes factors, Markov chain Monte Carlo, Ranking, Genome-
wide association studies.
1. Introduction
In the search for genetic markers that are responsible for heritable complex
human traits, whole-genome scans including genome-wide association studies
(GWAS) and the next generation sequencing (NGS) studies have made tremen-
dous progress; see www.genome.gov/gwastudies for the most recent summary
of GWAS findings by the National Human Genome Research Institute (Wel-
ter et al., 2014). The ‘whole-genome’ nature of these studies, however, is often
compromised by the omission of the X-chromosome (Heid et al., 2010; Teslovich
et al., 2010). In fact, it was found that “only 33% (242 out of 743 papers) re-
ported including the X-chromosome in analyses” based on the NHGRI GWAS
Catalog (Wise et al., 2013). The exclusion of X-chromosome from GWAS and
NGS is due to it being fundamentally different between females and males. In
contrast to the 22 autosomal chromosomes where both females and males have
∗To whom correspondence should be addressed.
1
ar
X
iv
:1
70
4.
01
20
7v
2 
 [s
tat
.A
P]
  2
5 J
un
 20
17
B. Chen et al./BMA for the XCI Dilemma in GWAS 2
two copies, females have two copies of X-chromosome (XX) while males have
only one X coupled with one Y-chromosome (XY). Thus, statistical association
methods well developed for analyzing autosomes require additional considera-
tions for valid and powerful application to X-chromosome.
Focusing on the single nucleotide polymorphisms (SNPs) as the genetic mark-
ers of interest here and without loss of generality, let d and D be the two alleles
of a SNP and D be the risk allele. An X-chromosome SNP in females has three
possible (unordered) genotypes, dd, dD and DD, in contrast to d and D in
males. Suppose each copy of the D allele has an effect size of β on the outcome
of interest; this β is the coefficient in linear regression for studying (approxi-
mately) normally distributed outcomes, or the log odds ratio in logistic regres-
sion for analyzing binary traits. To ensure “dosage compensation for X-linked
gene products between XX females and XY males”, X-chromosome inactivation
(XCI) may occur so that one of the two alleles in females is randomly selected
to be silenced (Gendrel & Heard, 2011). In other words, the effects of dd, dD
and DD in females are now respectively 0, β/2 and β on average after XCI vs.
0, β and 2β without XCI. However, without collecting additional biological data
the status of XCI is unknown.
Previous work on developing association methods for X-chromosome SNPs
mostly focused on issues other than XCI, including the assumptions of Hardy-
Weinberg equilibrium (HWE) and equal allele frequencies or sample sizes be-
tween female and males (Zheng et al., 2007; Clayton, 2008). In his classic review
paper, Clayton (2009) also discussed analytical strategies for multi-population
or family-based studies. In each of these cases, either the XCI or no-XCI model
is assumed, and naturally these methods work well only if the underlying as-
sumption about the XCI status is correct (Loley et al., 2011; Hickey & Bahlo,
2011; Konig et al., 2014).
More recently, Wang et al. (2014) recognized the problem and proposed a
maximum likelihood approach. In essence, the proposed method calculates mul-
tiple association statistics for testing the effect of a X-chromosome SNP under
XCI and no XCI models, then uses the maximum. To adjust for the inherent
selection bias, the method uses a permutation-based procedure to obtain the
empirical distribution for the maximal test statistic and assess its significance.
Although Wang et al.’s method appears to be adequate in terms of association
testing, in the presence of model uncertainty it is not clear how to construct a
point estimate or confidence interval for effect size β, or, what is a suitable mea-
sure of evidence for supporting one model over the other. Thus, an alternative
paradigm that directly accounts for the inherent model uncertainty is desirable.
To close this gap, we propose a Bayesian approach that can handle in a
principled manner the uncertainty about the XCI status. The use of Bayesian
methods for genetic association studies is not new. Stephens & Balding (2009)
and Craiu & Sun (2014) provide reviews in the context of studying autosome
SNPs. Here we consider the posterior distributions generated from Bayesian
regression models for analyzing X-chromosome SNPs under the XCI and no
XCI assumptions. We combine the estimates from the two models following the
Bayesian model averaging (BMA) principle that has long been recognized as
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a proper method for incorporating model uncertainty in a Bayesian analysis
(Draper, 1995; Hoeting et al., 1999). We calculate the BMA-based highest pos-
terior density (HPD) region for the parameter of interest. The BMA posterior
distribution is directly interpretable as a weighted average for β, averaged over
the XCI and no XCI models with more weight given to the one with stronger
support from the data. To rank multiple SNPs, we calculate Bayes factors com-
paring the averaged model with the null model of no association for each SNP.
In Section 2, we present the theory of Bayesian model averaging for handling
the X-chromosome inactivation uncertainty issue. We first consider linear re-
gression models for studying continuous traits where closed-form solutions can
be derived. We then discuss extension to logistic models for analyzing binary
outcomes where Markov chain Monte Carlo (MCMC) methods are used for in-
ference. In this setting, the calculation of Bayes factors is no longer possible ana-
lytically so we implement numerical approximations that have been reliably used
in computing ratios of normalizing constants. To facilitate methods comparison,
we also provide an analytical solution for assessing significance of the maximum
statistic in the spirit of Wang et al. (2014), supplanting their permutation-based
approach. In Section 3, we conduct extensive simulation studies to evaluate the
performance of the proposed Bayesian approach. In Section 4, we apply the
method to a X-chromosome association study of meconium ileus, an intestinal
disease present in Cystic Fibrosis patients, providing further evidence of method
performance. In Section 5, we discuss possible extensions and future work.
2. Methods
2.1. Normally distributed outcomes
The methodology development here focuses on linear models, studying associa-
tion relationship between a (approximately) normally distributed trait/outcome
Y and a X-chromosome SNP. Let (dd, dD,DD) and (d,D) be the genotypes of a
SNP, respectively, for females and males. For autosome or X-chromosome SNPs
in females, genotypes dd, dD and DD are typically coded additively as 0, 1 and
2, representing the number of copies of a reference allele, assumed to be D here.
Under the X-chromosome inactivation (XCI) assumption, one of the two alleles
of a female is randomly selected to have no effect on the outcome. Thus, the
XCI and no XCI assumptions lead to two different coding schemes, respectively,
G1 and G2 as summarized in Table 1.
Let Y be the vector of outcome measures of sample size n, and Gk be the
vector of genotype values for the n individuals coded under model Mk, k = 1 and
2 as shown in Table 1. For each model Mk, we consider a linear regression model
Y = Xkθk + k, where Xk = (1n,Gk) is the design matrix, θk = (αk, βk)′ and
k ∼ N(0, σ2In). Here βk represents the genetic effect of one copy of D under
model Mk, k = 1,2, accounting for the effects of other covariates Zs such as
gender, age, smoking status and population information. For notation simplicity
and without loss of generality for implementing the following Bayesian model
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average framework, Zs are omitted from the regression model. The coding of
0.5 for genotype dD under M1 reflects the fact that the effect of dD under the
XCI assumption is the average of zero effect of d (if D was silenced) and β effect
of D (if d was silenced). In addition, 1 and 2 have the same variance σ
2In
because both models are based on same response variable Y .
Before we present the Bayesian approach, we make several important remarks
here. First, the regression model above studies the genotype of a SNP, thus it
does not require the assumption of HWE; only methods based on allele counts
are sensitive to the equilibrium assumption (Sasieni, 1997). Similarly, allele-
frequency affects only they efficiency of genotype-based association methods but
not the accuracy. In addition, although other types of genetic architecture are
possible, e.g. dD and DD having the same effect as in a dominant model or dd
and dD having the same effect as in a recessive model, the additive assumption
has its theoretical justification and sufficiently approximates many other models
(Hill et al., 2008).
2.2. A Bayesian model averaging approach
In practice, it is unknown which of the two models (M1 XCI and M2 no XCI )
is true. Instead of performing inference based on only one of the two models or
choosing the maximum one, the Bayesian model averaging (BMA) framework
naturally aggregates information from both M1 and M2. Central to BMA is the
Bayes factor (BF ) defined as
BF12 = P (Y ∣M1)
P (Y ∣M2) ,
where P (Y ∣Mk) = ∫ f(Y ∣θ, σ2,Mk)pi(θ∣σ2,Mk)pi(σ2∣Mk)dθdσ2 is the marginal
probability of the data under model Mk. Here we used the outcome variable Y
to denote all available data; meaning should be clear from the context.
We consider conjugate priors for pi(σ2∣Mk) and pi(θ∣σ2,Mk) for each model,
pi(σ2∣Mk) = pi(σ2) = IG(a0, b0) where IG(a0, b0) is the inverse gamma distribu-
tion with density function
p(σ2) = ba00
Γ(a0)(σ2)−a0−1 exp(− b0σ2 ) .
As noted before, Y is common between M1 and M2 so the prior distributions
of σ2 for the two models are the same. For pi(θ∣σ2,Mk) = pi(θk),
pi(θk) = N(µ0, σ2Λ−10k),
where Λ0k is the precision matrix (Wright, 2008). For hyperparameter Λ0k, we
adopt the g-prior (Zellner, 1986) that takes the form of Λ0k = λnX ′kXk. We note
that here the female component of G1 is half of that of G2. Thus, if we na¨ıvely
use pi(θk) = N(µ0, σ2λI2), this scaling factor can affect the Bayes factor and
the ensuing model average quantities; the model with smaller covariate values
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is always preferred even if rescaling is the only difference. We discuss further in
Section 5 the importance of using the g-prior form in this setting.
When estimating the posterior distribution of θ under each model, the effect
of the precision parameter λ is minimal, but this is not true for inferring whether
β = 0 or not using the Bayes factor. For the latter purpose, following the recom-
mendations in Kass & Raftery (1995) we use λ = 1. For other hyperparameters,
naturally µ0 = 0 unless there is prior information about association between
the SNP under the study and the trait of interest. In the absence of additional
information for σ2, we let a0 = b0 = 0.1; setting a0 = b0 = 0 in simulation studies
did not lead to noticeable numerical difference compared to a0 = b0 = 0.1.
The likelihood function is defined by f(Y ∣θ, σ2,Mk) ∼ N(Xkθ, σ2In), which
yields a normal-inverse-gamma posterior distribution, and the corresponding
marginal distributions of θ and σ2 can be derived. Specifically, pi(θ, σ2∣Y,Mk),
the posterior distributions for (θ, σ2) under each model Mk, is a multivariate t
distribution with 2a degrees of freedom (df henceforth), location parameter µk
and scale parameter bk
a
Λ−1k , i.e., density function
pi(θ∣Y,Mk)∝ [1 + (θ −µk)′Λk(θ −µk)
2bk
]− 2a+22 ,
and the posterior of σ2 is pi(σ2∣Y,Mk) = IG(a, bk), where
Λk =X ′kXk +Λ0k (Λ0k = λnX ′kXk),
µk = Λ−1k (Λ0kµ0 +X ′kY ),
a = a0 + n
2
, and bk = b0 + 1
2
(Y ′Y +µ0′Λ0kµ0 −µ′kΛkµk).
Focusing on the primary parameter of interest here, we extract the slope
coefficient β from the posterior of θ = (α,β) under each model Mk. If we let
µk2 be the second element of µk, and (Λ−1k )22 be the (2,2)th entry in Λ−1k , we
obtain that β has univariate t distribution with 2a df and µk2 and
bk
a
(Λ−1k )22,
respectively, as the location and scale parameters, i.e.
pi(β∣Y,Mk) = µk2 + t2a√bk
a
(Λ−1k )22, (2.1)
where t2a is the standard t distribution with 2a df. The normalizing constant
for the posterior under model Mk is then
P (Y ∣Mk) = f(Y ∣θ, σ2,Mk)pi(θ∣σ2,Mk)pi(σ2∣Mk)
pi(θ, σ2∣Y,Mk) = 1(2pi)n/2
¿ÁÁÀ∣Λ0k ∣∣Λk ∣ ba00 Γ(a)bakΓ(a0) ,
which leads to the Bayes factor between M1 and M2 as
BF12 = ¿ÁÁÀ∣Λ2∣∣Λ1∣ × ∣Λ01∣∣Λ02∣ (b2b1 )a . (2.2)
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The BMA of two models takes the form of (Hoeting et al., 1999)
pi(θ, σ2∣Y ) = P (M1∣Y )pi(θ, σ2∣Y,M1) + P (M2∣Y )pi(θ, σ2∣Y,M2).
Let P (Y ) be the marginal probability of the data obtained after averaging over
both models,
P (Y ) = P (Y ∣M1)P (M1) + P (Y ∣M2)P (M2). (2.3)
In the absence of prior information, it is customary to assume equal prior prob-
abilities for the two models, i.e. P (M1) = P (M2) = 0.5. Therefore we have
pi(θ, σ2∣Y ) = P (Y ∣M1)P (M1)
P (Y ∣M1)P (M1) + P (Y ∣M2)P (M2)pi(θ, σ2∣Y,M1)
+ P (Y ∣M2)P (M2)
P (Y ∣M1)P (M1) + P (Y ∣M2)P (M2)pi(θ, σ2∣Y,M2)
= BF12
1 +BF12pi(θ, σ2∣Y,M1) + 11 +BF12pi(θ, σ2∣Y,M2). (2.4)
Note that the posterior distribution pi(θ, σ2∣Y ), which we call BMA posterior, is
a mixture of the two posterior distributions resulting from models M1 and M2.
Because it is not obtained from a given sampling distribution and a particular
prior, it may not be a canonical posterior.
The BMA posterior relies on the Bayes factor as the weighting factor, favour-
ing one model over using weights based on BF12. Given an established associ-
ation, we expect the Bayes factor provide evidence supporting one of the two
models. Intuitively, if BF12 > 1 then we have more support for M1 from the data
and vice versa when BF12 < 1. For the priors considered here, we show in the
Supplementary Materials that when data was generated from M1, Y =X1θ1+1,
BF12
p→∞ as n→∞ for any values of the hyperparameters, and similarly when
Y =X2θ2+2, BF12 p→ 0. This is also consistent with our empirical observations
from simulation studies, supporting the use of Bayes factor for model selection
in this setting.
2.3. BMA-based highest posterior density interval for the genetic
effect of a SNP
There are multiple ways to assess the genetic effect of a SNP based on the
posterior distribution of β. The simpler approach is to use the posterior mode
of β as a point estimate. The highest posterior density (HPD) region however
provides more information with an interval estimate. To calculate BMA-based
HPD, we note that the posterior density of β from each of the M1 and M2 models
is a univariate t with location and scale parameters as specified in equation (2.1).
The BMA posterior of β is therefore a mixture of two known t distributions with
the mixture proportion depending on BF12. It is thus possible to calculate the
exact HPD region for β.
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A (1−α)% HPD is defined as R(cα) = {β ∶ pi(β∣Y ) ≥ cα}, where pi(β∣Y ) is the
BMA posterior density of β and cα is the threshold such that the area under the
posterior density is 1−α. Depending on the similarity between the two posterior
distributions corresponding to M1 and M2 for a given credible level α, a BMA
HPD region can be either one single interval or made up of two disconnected
intervals. In all examples we have studied the HPD region is a single interval at
α = 0.05. Specifically, let βl and βu to be the two solutions of pi−1(cα). The 1−α
HPD region is then (βl, βu), where
∫ βu
βl
pi(β∣Y )dβ = 1 − α,
pi(βl∣Y ) = pi(βu∣Y ) = cα. (2.5)
The closed form of pi(β∣Y ) is in fact available, thus we can solve the equations
defined in (2.5) numerically to find cα as well as βl and βu, using function
multiroot in R package rootSolve. Note that for notation simplicity, we use
α here to denote the desired credible level; its distinction from the intercept
parameter, also denoted by α, should be clear from the context.
2.4. Assessing genetic effect and ranking multiple SNPs by Bayes
factor
In Bayesian framework, the significance of a SNP can be evaluated using Bayes
factor (Kass & Raftery, 1995; Stephens & Balding, 2009). In the presence of
model uncertainty, we propose using the Bayes factor calculated by comparing
the averaging model between M1 and M2 with the null model of no effect, MN .
Under the null model of β = 0, let XN = 1n be the corresponding design matrix.
Using the same prior distributions and hyperparameter values for the remaining
parameters, σ2 and α, the calculation of P (Y ∣MN) is then similar to that of
P (Y ∣M1) and P (Y ∣M2) as described in Section 2.2. Let
BF1N = P (Y ∣M1)
P (Y ∣MN) , BF2N = P (Y ∣M2)P (Y ∣MN)
be the Bayes factors comparing, respectively, the XCI M1 and no XCI M2 with
the null model MN , the Bayes factor for comparing the averaging model with
the null model is defined as
BFAN = P (Y ∣M1)P (M1) + P (Y ∣M2)P (M2)
P (Y ∣MN) .
Because P (M1) = P (M2) = 0.5 in our setting, we thus have
BFAN = 1
2
(BF1N +BF2N). (2.6)
The Bayes factor BFAN has similar asymptotic properties as BF12. We show in
the Supplementary Materials that in our setting if λ > 0 (the precision parameter
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for β), then BFAN converges in probability to either 0 or ∞, depending on
whether β = 0 or not.
In practice, besides assessing association evidence for a single SNP, scientists
are often interested in ranking multiple SNPs from a whole-genome scan and
selecting the top ones for follow up studies. The (conservative) lower bounds of
the HPD intervals (and the BFs) can be used for this purpose, and we demon-
strate this in Section 4 where we rank over 14,000 X-chromosome SNPs studying
their association evidence with meconium ileus in Cystic Fibrosis patients.
2.5. Binary outcomes
When we measure binary responses, M1 and M2 are logistic regression models.
Assuming the prior θk ∼ N(µ0,Λ−10k), the BMA framework described above
can still be used although computational complexities arise due to the lack of
conjugacy. Given its superior performance (Choi & Hobert, 2013), we use the
Polya-Gamma sampler of Polson et al. (2013) and the R package BayesLogit
to draw samples from the posterior distributions under M1 and M2. To obtain
samples from the averaged model, we draw samples from M1 with probability
BF12/(1 +BF12) and from M2 with probability 1/(1 +BF12) based on equation
(2.4). And we use these samples to construct the 1 − α HPD interval via the
function HPDinterval in the R package coda.
The calculation of BF12 is based on the Bridge sampling method proposed
by Meng & Wong (1996) and further refined by Gelman & Meng (1998) which
we delineate below. Suppose we have J posterior samples, θkj , from the two
models, k = 1 and 2 and j = 1, ..., J . For each parameter sample θkj , we can
calculate the corresponding unnormalized posterior density based on the logistic
model under the M1 XCI assumption,
q1(θkj) = pi(θkj ∣M1)f(Y ∣θkj ,M1)= pi1(θkj) n∏
i=1 p1i(θkj)Yi(1 − p1i(θkj))1−Yi ,
where p1i(θkj) = [1 + exp(−X1iθkj)]−1, and X1i is the ith row of the design
matrix X1 that contains the genotype data coded under model M1 for the ith
individual. pi1 is the density function of N(µ0,Λ−101). Similarly we obtain
q2(θkj) = pi(θkj ∣M2)f(Y ∣θkj ,M2)= pi2(θkj) n∏
i=1 p2i(θkj)Yi(1 − p2i(θkj))1−Yi ,
where p2i(θkj) = [1 + exp(−X2iθkj)]−1 under model M2, and pi2 is the density
function of N(µ0,Λ−102). We then define the ratio of unnormalized densities as
lkj = q1(θkj)/q2(θkj) and compute the Bayes factor iteratively. Specifically, we
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set BF
(1)
12 = 1 and compute at the (t + 1)th iteration until convergence,
BF
(t+1)
12 = ∑Jj=1 l2jl2j+BF (t)12∑Jj=1 1l1j+BF (t)12 . (2.7)
When comparing the averaged model vs. null model, the above procedure can-
not be directly implemented to calculate BF1N and BF2N , since the null model
has different dimension of parameter θ. Instead of finding the ratio of normaliz-
ing constants by the numerical method above, we find P (Y ∣M1), P (Y ∣M2) and
P (Y ∣MN) by calculating the ratio between them and known quantities. The lat-
ter will be the normalizing constants corresponding to Gaussian approximations
of the posterior distributions of interest. More precisely, we use the following
steps:
• To calculate P (Y ∣M1), we approximate the posterior under M1 using a
bivariate normal distribution with independent components. So we find
the sample mean and sample variance of posterior sample θ1j = (α1j , β1j),
which are (α¯1, β¯1) and ( s2α1 00 s2β1 ).
• We simulate α′1j and β′1j from the above bivariate approximation to the
posterior whose normalizing constant is c1 = 2pisα1sβ1 and set θ′1j =(α′1j , β′1j).
• We use the iterative approach in equation (2.7) to compute the ratio of nor-
malizing constants between the posterior under M1 and the corresponding
approximation, BF1 = P (Y ∣M1)/c1. Since c1 is known, we can easily derive
the normalizing constant P (Y ∣M1).
• To calculate P (Y ∣MN), we repeat the procedure used for P (Y ∣M1) but
this time the dimension of the parameter is one instead of two.
• The unnormalized posterior density for MN is
qN(θNj) = pi(θNj ∣MN)f(Y ∣θNj ,MN)= piN(θNj) n∏
i=1 pN(θNj)Yi(1 − pN(θNj))1−Yi ,
where pN(θNj) = [1+exp(−θNj)]−1, and piN is the prior density ofN(0, λ−1).
• We then use equation (2.7) to compute BFN = P (Y ∣MN)/cN , and we
obtain BF1N as
BF1N = BF1
BFN
× c1
cN
.
• We repeat the above steps for M2 to calculate BF2N .
• Finally, we use equation (2.6) to calculate BFAN by averaging BF1N and
BF2N .
2.6. Revisit the maximum likelihood approach of Wang et al. (2014)
Let Z1 and Z2 be the frequentist’s test statistics for testing βk = 0 derived from
the two regression models, Y = αk + βkGk + k, k = 1 and 2, respectively under
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the XCI M1 and no XCI M2 assumptions; Gk are the corresponding genotype
codings as shown in Table 1. The maximum likelihood approach of Wang et al.
(2014), in essence, uses Zmax =max(∣Z1∣, ∣Z2∣) as the test statistic and calculates
the p-value of Zmax empirically via a permutation-based procedure. Instead of
obtaining p-values using a permutation-based method as discussed in Wang et al.
(2014), we note that the significance of Zmax can be obtained more efficiently.
Under the null hypothesis of no association for either linear or logistic regression,
Z1 and Z2 have an approximate bivariate normal distribution, N(0,Σ) and
Σ = ( 1 ρZ1,Z2
ρZ1,Z2 1
), where conditional on the observed genotypes G1 and
G2, ρZ1∣G1,Z2∣G2 = rG1,G2 , where rG1,G2 is the sample correlation of G1 and
G2. This principle has been used in another setting where for an un-genotyped
SNP, instead of imputing the missing genotype data, the association statistic
is directly inferred based on the association statistic at a genotyped SNP and
the correlation between the two SNPs estimated from a reference sample (Lee
et al., 2013; Pasaniuc et al., 2014). Thus, given the two genotype codings of
each SNP, without permutation we can find the threshold value z1−α for the
maximum statistic Zmax at the nominal type I error rate of α. In application
study below (Section 4), for each of the 14,000 or so SNPs analyzed, we will
obtain the corresponding p-value using this method.
3. Simulation Study
We conduct simulation studies to evaluate the performance of the proposed
Bayesian model averaging methods for studying both normally distributed traits
and binary outcomes. Here we focus on the performance quantities relevant to
Bayesian methods, including the BMA HPD internals of Section 2.3 and the
BMA BF of Section 2.4. We leave the ranking comparison with the frequentist
method of Wang et al. (2014) to the application study in Section 4.
3.1. Simulation settings
In our simulations, we vary the sample size n, proportion of males and fre-
quencies of allele D for males and females (pm and pf respectively). In each
case we first generate data for G, where we simulate female genotypes using
a multinomial distribution with probabilities of (1 − pf)2, 2pf(1 − pf) and p2f ,
respectively, for dd, dD and DD, and we simulate male genotypes using a bino-
mial distribution with probabilities of (1 − pm) and pm, respectively, for d and
D.
We then generate outcome data for Y based on the simulated G coded under
the XCI M1 or no XCI M2 assumption, and various parameter values of the
regression models. For linear models we fix α = 0; the intercept parameter has
negligible effects on result interpretation (e.g. α = 1 lead to similar conclusion).
Without loss of generality, we also fix σ2 = 1. Under the null model, β = 0 and
Y does not depend on the XCI and no XCI assumptions, i.e. Y ∼ N(0, σ2In).
B. Chen et al./BMA for the XCI Dilemma in GWAS 11
Under alternatives and for each Mk, method performance depends on both
genetic effect size β and allele frequencies pm and pf , via the quantity EV ,
the variation of Y explained by genotype, where EV = V ar(E(Y ∣G))/V ar(Y ).
Although allele frequencies affect method performance as we will see in the
application study below, fixing EV instead of β has the benefit of not requiring
specification of the relationship between β and allele frequencies (e.g. variants
with lower frequencies tend to have bigger effects or smaller effects, vs. the
two parameters are independent of each other); Derkach et al. (2014) explored
this in a frequentist setting for jointly analyzing multiple autosome SNPs. For
linear models, it is easy to show that EV = β2σ2G/(β2σ2G + σ2), where σ2G is
the variance of G depending on pm and pf . Thus, for a given EV value we
obtain β = σ/σG ⋅√EV /(1 −EV ) for different choices of pm and pf and codings
of G for Mk, k = 1 and 2. We then simulate Y for continuous outcomes from
N(Xkθ, σ2In) based on θ = (α,β) and Xk = (1n,Gk).
For studying binary outcomes using logistic regression, we assume the typical
study design of equal numbers of cases and controls. Under the null of β = 0,
we randomly assign Y = 0 to half of the sample and Y = 1 to the other half.
Under alternatives, the derivation of β given EV and allele frequencies is a bit
more involved, and we outline the details in the Supplementary Materials. We
then simulate Y from Bin(n∗, (1 + exp(−Xkθ))−1), n∗ > n, until n/2 numbers
of cases and controls are generated.
To summarize, the parameters involved in the simulation studies include the
sample size (n and the proportion of males), allele frequencies in males and
females (pm and pf ), the variation of Y explained by genotype (EV and in
turn β; without loss of generality (w.l.g.), α = 0, σ2 = 1), as well as equal
numbers of cases and controls for studying binary traits. In the following, we
show representative results when n = 1000 (and assuming the proportion of
males is half), EV = 0.005 or 0.01, and pm and pf ranging from 0.1 to 0.9 where
the two frequencies do not have to be equal but have to be both ≥ 0.5 or ≤ 0.5;
in practice it is unlikely that the difference in allele frequencies is so big that
the reference alleles in males and females differ. The number of MCMC samples
for analyzing each binary dataset is J = 1000.
3.2. Performance of the Bayesian methods
We provide BMA-based HPD intervals and their corresponding BFAN on the
log10 scale for 50 independent data replicates simulated under different condi-
tions for logistic regression models in Figures 1 and 2; results for linear models
are provided in the Supplementary Materials. The intervals are sorted by their
lower bounds. In the left-panel of each figure, the blue dashed line marks β = 0
and the red solid line marks the true value of β; two lines overlap under the
null. In the right panel, the blue dashed line marks log10(BFAN) = 0, and the
red solid line marks the conventional threshold of log10(BFAN) = 1 for declaring
strong evidence favouring one model over the other (Kass & Raftery, 1995).
Figures 1 present the results under the null of no association where EV = 0
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(i.e. β = 0). The top panel is for unequal male and female allele frequencies at
(pm, pf )=(0.1, 0.3), and the bottom panel is for (pm, pf )=(0.3, 0.3); results for
other allele frequency values (e.g. (0.5, 0.3), (0.5, 0.7), (0.7, 0.7) and (0.9, 0.7))
are similar and provided in the Supplementary Materials. We note that although
the HPD intervals do not have the same coverage interpretation as CI, just over
95% of the HPD intervals contain zero. Similarly, most of the values are less
than zero, i.e. BFAN < 1; additional simulations show that BFAN decrease as
the sample size increases under the null.
Figures 2 presents the results under different alternatives, where (pm, pf )=(0.1,
0.3) and data are simulated from the XCI M1 model, but EV varies and
EV=0.005 for the top panel and EV=0.01 for the bottom; results for other
parameter values and data simulated from M2 are similar and are included in
the Supplementary Materials. It is clear that as EV increases, the performance
of the proposed Bayesian methods increases.
4. Application Study
Sun et al. (2012) performed a whole-genome association scan on meconium ileus,
a binary intestinal disease occurring in about 20% of the individuals with Cystic
Fibrosis. Their GWAS included X-chromosome but assumed the inactivation M1
model. They identified a gene called SLCA14 to be associated with meconium
ileus, and in their Table 2 they reported p-values in the range of 10−12, 10−8 and
10−6, respectively, for rs3788766, rs5905283 and rs12839137 from the region. We
revisit this data by applying the maximum likelihood approach (or the minimal
p-value of the XCI M1 and no XCI M2 models) and the proposed Bayesian
model average method.
The data consists of n = 3199 independent CF patients, and there are slightly
more males (nm = 1722, 53.8%) than females (nf = 1477). Among the study
subjects, 574 are cases with meconium ileus and 2625 are controls, and the
rates of meconium ileus (17.7% vs. 18.3%) do not appear to differ between
the male and female groups. Genotypes are available for 14280 X-chromosome
SNPs, but 60 are monomorphic (no variation in the genotypes). Thus association
analysis is performed between each of the 14220 X-chromosome SNPs and the
binary outcome of interest. That is, 14220 p-values and 14220 BMA BFs and
HPD intervals are calculated and investigated. By convention, for each SNP we
assume the minor allele as the risk allele D and we use the two coding schemes
as described in Table 1 under the M1 and M2 models.
Figure 3 shows the QQplots of p-values obtained using the frequentist frame-
work. The left graph is under the M1 inactivation assumption as in the original
analysis of (Sun et al., 2012). The middle one is under the M2 no inactivation
assumption. And the right one is based on the minimal p-values adjusted for
selecting the best of the two models using the asymptotic approximation as dis-
cussed in Section 2.6. As expected, most of the SNPs are from the null, but there
are four clear outliers/signals with evidence for association with meconium ileus
regardless of the methods used. The overall consistency between the M1 and M2
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models is the result of high correlation between Z1 and Z2; we discuss this point
further in Section 5 below. Contrasting the left graph with the middle one in
Figure 3 shows that the XCI M1 assumption lead to smaller p-values for these
four SNPs than the no XCI M2 assumption. Table 2 provides the corresponding
minor allele frequencies (MAF, pooled estimates because sex-specific estimates
are very similar to each other), log OR estimates and p-values for these four
SNPs.
Figure 4 present the Bayesian results for top 50 ranked SNPs. Similarly to the
presentation of the simulation results in Section 3, in the left graph SNPs are
ranked based on the lower bounds of their BMA-based HPD intervals, and the
corresponding log10(BFAN) values are provided one the right. Table 3 provides
more detailed results for top 15 SNPs including the BF12 comparing M1 with
M2. Note that for ease of presentation and without loss of generality we mirror
all negative intervals to positive ones.
Two important remarks can be made here. First, the proposed Bayesian
method clearly identifies the four SNPs suggested by the p-value approach. Sec-
ond, the Bayesian framework in this setting provides more feature-rich quanti-
ties, and it pinpoints additional SNPs that merit follow-up studies. Note that
although p-values lead to similar rankings between the two models themselves,
they could miss potentially important SNPs. Taking rs12689325 as an example,
this SNP will not be identified with a rank of 331 based on the p-value of 0.0268,
the adjusted minimum of p-values calculated under M1 and M2. However, this
SNP ranks second based on the (conservative) lower bounds of the BMA-based
HPD intervals averaged over M1 and M2 (Figure 4 and Table 3). The wide
BMA HPD interval is a result of small MAF (1.3%) coupled with a moderate
effect size. Given a trait of interest in practice, if genetic etiology implies the in-
volvement of rare variants, the Bayesian results suggest that this SNP warrants
additional investigation.
5. Discussion
We propose a Bayesian approach to address the ambiguity involved in GWAS
and NGS studies of SNPs situated on the X-chromosome. Depending on whether
X-inactivation takes place or not, there are two regression models that can be
used to explore the genetic effect of a given SNP on the phenotype of interest.
The proposed method allows us to produce posterior-based inference that incor-
porates the uncertainty within and between genetic models. While the former
is quantified by the posterior distribution under each model, the latter can be
properly accounted for by considering a weighted average of the model-specific
estimators. Following the Bayesian paradigm, the weights are proportional to
the Bayes factor comparing the two competing models. The asymptotic proper-
ties of the Bayes factors considered in this paper for linear models are included in
the Supplementary Materials. In the binary response case, the theoretical study
is difficult due to the intractable posteriors, but the Monte Carlo estimators
exhibit good properties in all the numerical studies performed.
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The use of g-priors in this study setting is essential in that it allows us to
avoid the effect of covariate rescaling on the Bayes factors, yet maintain results
interpretation. In regression models, we know that the effect size β is inversely
proportional to the size of the covariate value/genotype coding. Given a set
of data, using X/2 or X should lead to identical inference. However, without
g-priors, a model with smaller covariate value would be preferred based on
BF . In our setting, the female component of the design matrix under the XCI
M1 coding is only half of that no XCI M2 coding; male codings are the same
for the two models. Consider the null case of β = 0 when the two competing
models are identical. Using Λ0k = λI for the precision of θk, we see that 80%
of BF12 are greater than one, suggesting M1 is preferred simply because of
its smaller genotype coding. One statistical solution is to rescale the design
matrix prior to the Bayesian inference. However, it is important to note that
the coding difference for females is driven by a specific biological consideration,
thus rescaling leads to difficulties in results interpretation. Instead, we use a g-
prior in Section 2. Indeed, simulation results for the null case show that BF12 > 1
in about 50% of replicates, indicating proper calibration.
The application has shown that the two models/assumptions lead to similar
results, and one may argue that the practical benefits of using BMA-based in-
ference is limited. However, It’s important to note that while the wrong model
may still lead to an average log(BF ) greater than one for a SNP, it signifi-
cantly impacts the ranking of the SNP; in practice only a few top ranked SNPs
receive the (often much more costly) biological experiments. Further, the simi-
larity between the two models depends on the sample correlation between the
covariates in the two models, rG1,G2 , which in turn depends on the allele fre-
quency of the reference allele. In the Supplementary Materials, we derive the
theoretical correlation, ρG1,G2 , as a function of allele frequencies in males and
females (pm, pf), and we show that when min{pm, pf} is not close to 1, G1
and G2 are indeed highly correlated. But when both pm and pf are large (e.g.
pm = pf = 0.95), the correlation can be lower than 0.5. In that case, the two
models will likely lead to different conclusions while the BMA-based approach
remains robust. To illustrate, consider the linear model as before (n = 1000,
EV = 0.01) but pm = pf = 0.95 and the true simulating model is either M1
or M2. Table 4 shows the average of log10BF1N , log10BF2N and log10BFAN
obtained from 1000 simulation replicates. Results here clearly demonstrate the
merits of the proposed BMA-based approach. Additional simulations assuming
a bigger effect (EV = 0.05) show that the averages of log10BF1N , log10BF2N
and log10BFAN are, respectively, 22.35, 2.29 and 21.65, if the true generating
model is M1. Even if the frequencies are not extreme, say pm = pf = 0.3 as in
the application study, the averaged BMA-based quantity is clearly more robust
as shown in Table 4, where the BMA-based log10BFAN = 1.755, though not as
high as log10BF1N = 1.942 using the ideal (unknown) true model M1, is clearly
a substantial improvement over log10BF2N = 1.062 using the incorrect model
M2.
When the allele frequency is on the boundary, we have commented that the
resulting HPD intervals can be quite wide as seen in the application above e.g.
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rs12689325 with MAF of 1.3%, the second ranked SNP in Figure 4; ranked 331
by the minimal p-value approach. Among the 14220 X-chromosome SNPs ana-
lyzed in Section 4, 829 SNPs have MAF less than 1%. In that case, there is little
variation in the genotype variable thus limited information available for infer-
ence. The top ranked SNPs thus were chosen from the remaining 13391 SNPs
with MAF greater than 1%. In recent years, joint analyses of multiple rare (or
common) variants (also known as the gene-based analyses) have received much
attention but only for autosome SNPs (Derkach et al., 2014). Extension to X-
chromosome SNPs remain an open question. Similarly, additional investigations
are needed for X-chromosome SNPs in the areas of family-based association
studies (Thornton et al., 2012), direct interaction studies (Cordell, 2009), as well
as indirect interaction studies via scale-test for variance heterogeneity (Soave &
Sun, 2016).
In Table 1, allele D is assumed to be the risk allele with frequency ranging
from 0 to 1, i.e. not necessary the minor allele. In practice as in our application,
the minor allele is often assumed to be the risk allele based on the known
genetic aetiology for complex traits. For autosome SNPs, it is well known that
coding D or d as the reference allele leads to identical inference with βD = −βd.
However, this is no longer true for analyzing X-chromosome SNPs under the
no XCI M2 model assumption; inference is identical under the XCI M1 model;
this was pointed out by (Wang et al., 2014) in their frequentist’s approach. To
see the difference empirically in our Bayesian setting, we revisit the CF data
as described in Section 4 and reanalyze SNP rs3788766 as a proof of principle.
Specifically, we first assume the minor allele D as the reference allele under the
XCI and no XCI assumptions, coded respectively as M1-D and M2-D. We then
assume d as the reference allele and consider the corresponding M1-d and M2-d
models. Table 5 shows the Bayes factor BFkN comparing each model with the
null model.
It is clear that the XCI M1 model is robust to the choice of the underly-
ing reference allele, i.e. M1-D and M1-d lead to identical association inference,
but this is not the case for M2-D and M2-d under the assumption of no XCI.
In hindsight this somewhat surprising results can be intuitively explained by
the fact that under M1, regardless of the choice of the reference allele, female
dd and male d genotypes belong to one group, DD and D belong to another
group and Dd itself is a group, i.e. ({dd, d}, dD,{DD,D}). Under M2 the three
groups are ({dd, d},{dD,D},DD) when D is the reference allele in contrast of(dd,{dD,d},{DD,D}) when d is the reference allele, thus resulting in differ-
ent association quantities. However, we also note that in practice when allele
frequencies are not close to the boundary as in this case (MAF = 0.388), the
empirical difference between M2-D and M2-d is not significant; we provide ad-
ditional application results in the Supplementary Materials. Nevertheless, it is
worth noting that the choice of reference allele is yet another analytical detail
that sets X-chromosome apart from the rest of the genome.
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Table 1
Genotype coding under the X-chromosome inactivation (XCI, M1) and no X-chromosome
inactivation (no XCI, M2) assumptions
Female Male
Model Coding dd dD DD d D
M1: XCI G1 0 0.5 1 0 1
M2: no XCI G2 0 1 2 0 1
Table 2
Summary of frequentist analysis of four top ranked SNPs, selected from analyzing
association evidence between 14220 X-chromosome SNPs and meconium ileus in 3199
Cystic Fibrosis patients. MAF is the pooled estimate of the frequency of the minor allele
(frequencies do not differ between males and females), log odds ratio estimates under the
XCI M1 and no XCI M2 assumptions, and their corresponding p-values and the (adjusted)
p-value of the minimal p-value or the maximal Z value.
Log Odds Ratios P-values
SNPs MAF M1 M2 M1 M2 Zmax
rs3788766 0.388 0.798 0.484 8.50e-12 2.20e-09 1.61e-11
rs5905283 0.487 0.586 0.326 4.79e-08 9.64e-06 8.88e-08
rs12839137 0.237 0.611 0.360 7.55e-06 5.44e-04 1.25e-05
rs5905284 0.249 0.592 0.358 8.61e-06 1.21e-04 1.43e-05
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Table 3
Summary of Bayesian analysis of 15 top ranked SNPs, selected from analyzing association
evidence between 14220 X-chromosome SNPs and meconium ileus in 3199 Cystic Fibrosis
patients. SNP are ordered based on their lower bounds of the BMA-average HPD intervals
for β.
HPD intervals Bayes factors
SNPs MAF Lower Upper BF12 BFAN
rs3788766 0.388 0.572 1.033 2.71e+02 1.49e+09
rs12689325 0.013 0.405 3.118 3.77e -01 3.28e+00
rs5905283 0.487 0.379 0.784 2.02e+02 8.71e+04
rs12845594 0.047 0.344 1.700 7.23e+00 8.61e+00
rs12839137 0.237 0.307 0.884 2.25e+01 1.34e+03
rs5905284 0.249 0.302 0.830 1.83e+01 1.08e+03
rs579854 0.136 0.266 0.932 1.88e+00 4.83e+01
rs5955417 0.030 0.260 2.130 3.28e+00 5.30e+00
rs12720074 0.100 0.237 0.943 5.33e -01 5.49e+01
rs1921965 0.091 0.228 0.893 1.34e+00 2.81e+01
rs6623182 0.036 0.217 1.216 2.89e+00 9.08e+00
rs3027514 0.015 0.209 1.496 8.34e -01 1.34e+00
rs17338514 0.099 0.201 0.821 1.19e+00 2.09e+01
rs11797786 0.068 0.191 0.947 4.68e+00 4.47e+00
rs1921967 0.122 0.190 0.756 7.50e -01 2.52e+01
Table 4
Summary of the average of log10 (Bayes factors) based on 1000 independent simulation
replicates. Allele frequency of D is 0.95 or 0.3 for both male and female, sample size is
1000, EV = 0.01, and data are simulated from the XCI M1 model or no XCI M2 model.
BF1N , BF2N and BFAN are the Bayes factors of M1 vs. the null MN model, the no XCI
M2 vs. MN , and the BMA-based model vs. MN .(pm, pf ) True Model log10BF1N log10BF2N log10BFAN(0.95,0.95) M1 2.066 -1.850 1.541(0.95,0.95) M2 -1.969 1.854 1.309(0.30,0.30) M1 1.942 1.062 1.755(0.30,0.30) M2 1.073 1.983 1.796
Table 5
Bayes factors of comparing models assuming different risk reference allele (D or d) and
genotype codings (XCI M1 or no XCI M2) of SNP rs3788766 with the null model, based on
the Cystic Fibrosis application data.
Female Male
Model dd dD DD d D BFkN
M1-D 0 0.5 1 0 1 2.97e+09
M1-d 1 0.5 0 1 0 2.97e+09
M2-D 0 1 2 0 1 8.21e+06
M2-d 2 1 0 1 0 1.74e+06
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Fig 1. BMA-based HPD intervals for β (left panel) and corresponding log10(BFAN ) (right
panel) for 50 replicates simulated based on null MN logistic model. Intervals are sorted by
their lower bounds. Male and female allele frequencies are (0.1,0.3) (top panel) and (0.3,0.3)
(bottom panel). In the left panel, the blue dashed line and red solid line overlap at the null
value of β = 0. In the right panel, the blue dashed line and red sold line mark, respectively,
log10(BFAN ) = 0 and = 1.
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Fig 2. BMA-based HPD intervals for β (left panel) and corresponding log10(BFAN ) (right
panel) for 50 replicates simulated based on XCI M1 logistic model. Intervals are sorted by
their lower bounds. Male and female allele frequencies are (0.1,0.3). In the left panel, the
blue dashed line marks the null value of β = 0, and the red solid line marks the true value
of β, determined so that EV = 0.005 (top panel) and EV = 0.01 (bottom panel). In the right
panel, the blue dashed line and red sold line mark, respectively, log10(BFAN ) = 0 and = 1.
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Fig 3. QQplots of −log10 p-values of analyzing association evidence between 14220 X-
chromosome SNPs and meconium ileus in 3199 Cystic Fibrosis patients, under the XCI M1
assumption (left), the no-XCI M2 assumption (middle) and using Zmax (right). Black circle● for rs3788766, blue up-pointing triangle ▲ for rs5905283, green square ∎ for rs12839137
and red down-pointing triangle ▼ for rs5905284.
Fig 4. BMA-based HPD intervals for β and corresponding log(BFAN ) for 50 top ranked
SNPs, selected from analyzing association evidence between 14220 X-chromosome SNPs and
meconium ileus in 3199 Cystic Fibrosis patients. SNP are ordered based on their lower bounds
of the HPD intervals. The four top SNPs identified by p-values are marked here using the
same symbol: black circle ● for rs3788766, blue up-pointing triangle ▲ for rs5905283, green
square ∎ for rs12839137 and red down-pointing triangle ▼ for rs5905284.
